Difficulty: Medium
Average Score: 87%
Practice
Which among the following beta-blockers is not potent than propranolol (considering propranolol = 1)?
Correct answer
D
Rationale
In this question, the correct answer is D) Labetalol. Labetalol is less potent than propranolol.
Rationale:
Labetalol is a non-selective beta-blocker with additional alpha-blocking properties. While it is effective in managing hypertension, its beta-blocking potency is less than that of propranolol. This makes it less potent in terms of beta-adrenergic receptor blockade compared to propranolol.
A) Carvedilol is a non-selective beta-blocker with alpha-blocking properties like labetalol but is more potent than propranolol.
B) Metoprolol is a selective beta-1 blocker and is less potent than propranolol.
C) Bisoprolol is a selective beta-1 blocker and is less potent than propranolol.
Educational Context:
Understanding the potency of beta-blockers is crucial in pharmacology, especially in managing cardiovascular conditions. Different beta-blockers have varying degrees of selectivity and potency, impacting their clinical efficacy and side effect profiles. Knowing the relative potency of these medications helps healthcare providers make informed decisions when selecting the most appropriate treatment for patients with cardiovascular conditions.
Rationale:
Labetalol is a non-selective beta-blocker with additional alpha-blocking properties. While it is effective in managing hypertension, its beta-blocking potency is less than that of propranolol. This makes it less potent in terms of beta-adrenergic receptor blockade compared to propranolol.
A) Carvedilol is a non-selective beta-blocker with alpha-blocking properties like labetalol but is more potent than propranolol.
B) Metoprolol is a selective beta-1 blocker and is less potent than propranolol.
C) Bisoprolol is a selective beta-1 blocker and is less potent than propranolol.
Educational Context:
Understanding the potency of beta-blockers is crucial in pharmacology, especially in managing cardiovascular conditions. Different beta-blockers have varying degrees of selectivity and potency, impacting their clinical efficacy and side effect profiles. Knowing the relative potency of these medications helps healthcare providers make informed decisions when selecting the most appropriate treatment for patients with cardiovascular conditions.